Abnormal structure-specific peptide transmission and processing in a primate model of Parkinson's disease and l-DOPA-induced dyskinesia

Neurobiology of Disease

Volumn 62, Issue , 2014, Pages 307-312

  Bourdenx, Mathieu ^a,b   Nilsson, Anna ^e   Wadensten, Henrik ^e   Fälth, Maria ^e   Li, Qin ^c,d   Crossman, Alan R ^c   Andrén, Per E ^e   Bezard, Erwan ^a,b,c,d  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

^c Williams House   (United Kingdom)

^d INSTITUTE OF LABORATORY ANIMAL SCIENCE   (China)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

L DOPA induced dyskinesia; Mass spectrometry; MPTP; Parkinson's disease; Peptides; Primate

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DYNORPHIN A; LEVODOPA; NEUROKININ A; PREPROTACHYKININ; PRODYNORPHIN; PROENKEPHALIN; SUBSTANCE P;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN FUNCTION; CONTROLLED STUDY; DISEASE SEVERITY; DYSKINESIA; EXPERIMENTAL ANIMAL; FEMALE; GLOBUS PALLIDUS; MASS SPECTROMETRY; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; PUTAMEN; QUANTITATIVE ANALYSIS; RHESUS MONKEY;

L-DOPA-INDUCED DYSKINESIA; MASS SPECTROMETRY; MPTP; PARKINSON'S DISEASE; PEPTIDES; PRIMATE;

ANIMALS; ANTIPARKINSON AGENTS; DYSKINESIA, DRUG-INDUCED; ENKEPHALINS; FEMALE; GLOBUS PALLIDUS; LEVODOPA; MACACA MULATTA; NEUROPEPTIDES; PARKINSONIAN DISORDERS; PROTEIN PRECURSORS; PUTAMEN; TACHYKININS;

EID: 84887351307     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.10.016     Document Type: Article

References (44)

1. Ahmed M.R., et al. Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease. Sci. Transl. Med. 2010, 2:28ra28.
2. Albin R.L., et al. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989, 12:366-375.
3. Aubert I., et al. Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia. Biol. Psychiatry 2007, 61:836-844.
4. Bezard E., et al. A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey. Brain Res. 1997, 766:107-112.
5. Bezard E., et al. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J. Neurosci. 2001, 21:6853-6861.
6. Bezard E., et al. Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine monkeys. Neurobiol. Dis. 2001, 8:343-350.
7. Cenci M.A., et al. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 1998, 10:2694-2706.
8. Fasano S., et al. Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:21824-21829.
9. Fernagut P.O., et al. Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys. PLoS One 2010, 5:e14053.
10. Fox S., et al. Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease. Mov. Disord. 2004, 19:554-560.
11. Fox S.H., et al. A critique of available scales and presentation of the Non-Human Primate Dyskinesia Rating Scale. Mov. Disord. 2012, 27:1373-1378.
12. Gentleman R.C., et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004, 5:R80.
13. Gerfen C.R., et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990, 250:1429-1432. (New York, NY).
14. Hanrieder J., et al. L-DOPA-induced dyskinesia is associated with regional increase of striatal dynorphin peptides as elucidated by imaging mass spectrometry. Mol. Cell. Proteomics 2011, 10, M111 009308.
15. Henry B., et al. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp. Neurol. 1999, 155:204-220.
16. Henry B., et al. Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Exp. Neurol. 2001, 171:139-146.
17. Henry B., et al. Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. Exp. Neurol. 2003, 183:458-468.
18. Imbert C., et al. Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey. J. Neurosci. Methods 2000, 96:71-76.
19. Kawaguchi Y., et al. Projection subtypes of rat neostriatal matrix cells revealed by intracellular injection of biocytin. J. Neurosci. 1990, 10:3421-3438.
20. Klintenberg R., Andren P.E. Altered extracellular striatal in vivo biotransformation of the opioid neuropeptide dynorphin A(1-17) in the unilateral 6-OHDA rat model of Parkinson's disease. J. Mass Spectrom. 2005, 40:261-270.
21. Koprich J.B., et al. The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease. Mov. Disord. 2011, 26:1225-1233.
22. Kultima K., et al. Development and evaluation of normalization methods for label-free relative quantification of endogenous peptides. Mol. Cell. Proteomics 2009, 8:2285-2295.
23. Liston D., et al. Processing of proenkephalin is tissue-specific. Science 1984, 225:734-737.
24. Maurice N., et al. Relationships between the prefrontal cortex and the basal ganglia in the rat: physiology of the cortico-nigral circuits. J. Neurosci. 1999, 19:4674-4681.
25. Merchenthaler I., et al. In situ hybridization histochemical localization of prodynorphin messenger RNA in the central nervous system of the rat. J. Comp. Neurol. 1997, 384:211-232.
26. Merg F., et al. Big dynorphin as a putative endogenous ligand for the kappa-opioid receptor. J. Neurochem. 2006, 97:292-301.
27. Morissette M., et al. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists. J. Neurochem. 1999, 72:682-692.
28. Munoz A., et al. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain 2008, 131:3380-3394.
29. Nadjar A., et al. Phenotype of striatofugal medium spiny neurons in parkinsonian and dyskinetic nonhuman primates: a call for a reappraisal of the functional organization of the basal ganglia. J. Neurosci. 2006, 26:8653-8661.
30. Nilsson A., et al. Striatal alterations of secretogranin-1, somatostatin, prodynorphin, and cholecystokinin peptides in an experimental mouse model of Parkinson disease. Mol. Cell. Proteomics 2009, 8:1094-1104.
31. Nisbet A.P., et al. Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease. Neuroscience 1995, 66:361-376.
32. Nyberg F., Hallberg M. Peptide conversion-a potential pathway modulating G-protein signaling. Curr. Drug Targets 2007, 8:147-154.
33. Parent A., et al. Organization of the basal ganglia: the importance of axonal collateralization. Trends Neurosci. 2000, 23:S20-S27.
34. Porras G., et al. PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking. J. Clin. Invest. 2012, 122:3977-3989.
35. Quik M., et al. Increases in striatal preproenkephalin gene expression are associated with nigrostriatal damage but not L-DOPA-induced dyskinesias in the squirrel monkey. Neuroscience 2002, 113:213-220.
36. Rascol O., et al. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. Mov. Disord. 1994, 9:437-440.
37. Santini E., et al. Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia. PLoS One 2010, 5:e12322.
38. Scholz B., et al. Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure. PLoS One 2008, 3:e1589.
39. Svensson M., et al. Peptidomics-based discovery of novel neuropeptides. J. Proteome Res. 2003, 2:213-219.
40. Svensson M., et al. Heat stabilization of the tissue proteome: a new technology for improved proteomics. J. Proteome Res. 2009, 8:974-981.
41. Tel B.C., et al. Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets. Neuroscience 2002, 115:1047-1058.
42. Valastro B., et al. Proteomic analysis of striatal proteins in the rat model of L-DOPA-induced dyskinesia. J. Neurochem. 2007, 102:1395-1409.
43. Westin J.E., et al. Persistent changes in striatal gene expression induced by long-term L-DOPA treatment in a rat model of Parkinson's disease. Eur. J. Neurosci. 2001, 14:1171-1176.
44. Wu H., et al. Maanova: Tools for Analyzing Micro Array Experiments, R package version 1.8.0 2007, Bioconductor, Seattle, WA.